List of Excipients in Branded Drug LANSOPRAZOLE DR

Generic Drugs Containing LANSOPRAZOLE DR

Company	Ingredient	NDC	Excipient
Direct_Rx	lansoprazole dr	72189-370	FD&C BLUE NO. 2
Direct_Rx	lansoprazole dr	72189-370	FERRIC OXIDE YELLOW
Direct_Rx	lansoprazole dr	72189-370	GELATIN
Direct_Rx	lansoprazole dr	72189-370	HYDROXYPROPYL CELLULOSE
Direct_Rx	lansoprazole dr	72189-370	MAGNESIUM CARBONATE

What are the Most Frequently-Used Excipients in LANSOPRAZOLE DR?

# Of NDCs	Excipient
1	FD&C BLUE NO. 2
1	FERRIC OXIDE YELLOW
1	GELATIN
1	HYDROXYPROPYL CELLULOSE
1	MAGNESIUM CARBONATE

Lansoprazole DR Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Lansoprazole delayed-release, or lansoprazole DR, is a mature generic proton-pump inhibitor market with limited molecule-level exclusivity but continuing formulation opportunities. The active ingredient is acid-labile, so commercial products depend on multiparticulate enteric protection rather than a conventional immediate-release tablet. The strongest opportunities are pediatric administration, stable liquid or sprinkle presentations, manufacturing-cost reduction, differentiated dissolution performance, and regional products aligned with local excipient regulations.

What excipient strategy is required for lansoprazole DR?

Lansoprazole DR requires an acid-protective dosage form. The formulation must prevent meaningful drug release in gastric acid and then release lansoprazole rapidly after exposure to the higher-pH intestinal environment.

The standard architecture is:

1. Inert starter core or drug-containing pellet.
2. Drug layer containing lansoprazole and binding or suspending excipients.
3. Protective seal coat.
4. Enteric polymer coat.
5. Capsule, orally disintegrating tablet, suspension, or other final dosage form.

Lansoprazole is unstable in acidic conditions. Enteric-coated pellets or granules are therefore the primary technical platform for capsules and orally disintegrating products. The formulation target is not simply delayed disintegration. It is protection against gastric degradation followed by prompt release at intestinal pH.

Which excipients are used in lansoprazole DR formulations?

A commercial lansoprazole DR formulation may use the following excipient classes:

Formulation layer	Typical excipient class	Technical purpose
Drug core	Sucrose spheres, microcrystalline cellulose, or other inert carrier	Provides a uniform surface for drug layering
Drug layer	Hydroxypropyl cellulose, hypromellose, povidone	Binds lansoprazole to the core
Alkalizing phase	Magnesium carbonate, magnesium oxide, or other alkaline material	Limits acid exposure and supports drug stability
Seal coat	Hypromellose, hydroxypropyl cellulose, polyethylene glycol	Separates drug layer from enteric polymer
Enteric coat	Methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate, or polyvinyl acetate phthalate	Prevents release in gastric fluid
Plasticizer	Triethyl citrate, acetyl tributyl citrate, polyethylene glycol	Improves film flexibility
Anti-tacking agent	Talc, glyceryl monostearate, colloidal silicon dioxide	Reduces pellet agglomeration
Capsule shell	Gelatin or hypromellose	Delivers enteric-coated pellets
ODT matrix	Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, microcrystalline cellulose	Supports rapid tablet disintegration and acceptable mouthfeel
Suspension vehicle	Suspending agent, sweetener, buffer, flavor, and preservative system	Enables administration to patients who cannot swallow capsules

The exact composition differs by manufacturer and strength. FDA labeling identifies inactive ingredients for approved products, while the FDA Inactive Ingredient Database provides a reference point for prior use by route and dosage form [1,2].

How should the core and drug layer be designed?

The drug-layer design determines content uniformity, pellet yield, dissolution, and stability. A robust commercial process generally requires narrow pellet-size distribution and consistent coating weight gain.

Key design variables include:

• Drug loading per pellet.
• Particle-size distribution of lansoprazole.
• Binder concentration.
• Spray rate and atomization pressure.
• Inlet and product temperature.
• Moisture exposure during layering.
• Alkaline excipient selection.
• Pellet friability and attrition.
• Coating thickness and uniformity.

An alkaline microenvironment can improve lansoprazole stability, but excessive alkalinity may affect dissolution, impurity formation, taste, and compatibility with coating materials. The formulation must balance chemical stabilization with rapid post-gastric release.

Sucrose-based nonpareils support established fluid-bed coating processes and are widely familiar to contract manufacturers. Microcrystalline cellulose or other alternative cores can reduce sugar content, alter density, and change coating behavior. Core substitution can create a manufacturing advantage, but it requires comparative dissolution, stability, and process validation.

Which enteric polymers are most commercially useful?

Methacrylic acid copolymers are generally attractive because they offer established pharmaceutical use, scalable aqueous or organic coating systems, and pH-dependent dissolution. The polymer grade must match the intended release threshold.

Important formulation choices include:

• Polymer type and dissolution pH.
• Aqueous versus organic coating process.
• Plasticizer level.
• Talc-to-polymer ratio.
• Seal-coat thickness.
• Coating weight gain.
• Residual solvent or residual moisture profile.
• Storage sensitivity after coating.

A lower-pH-triggered coating may promote earlier intestinal release, while a higher-pH-triggered system may provide greater gastric protection. The selection must be supported by acid-stage and buffer-stage dissolution data, not by polymer identity alone.

What formulations are protected by lansoprazole DR patents?

Most foundational lansoprazole composition and delayed-release technology is old and no longer provides meaningful U.S. exclusivity. The principal commercial protection today is more likely to arise from manufacturing know-how, process controls, product-specific formulation patents in selected jurisdictions, trademarks, regulatory data, and customer or channel agreements.

Legacy Prevacid patents covered lansoprazole, pharmaceutical compositions, delayed-release dosage forms, and related delivery approaches. The relevant patent families have generally expired after the original branded launch period. The FDA Orange Book remains the primary source for listed patents and regulatory exclusivity associated with specific approved products [3].

A new formulation patent could still be possible where the product has a non-obvious combination of:

• Improved stability.
• Lower impurity formation.
• Reduced coating weight.
• Faster intestinal release.
• Improved moisture resistance.
• A novel liquid or pediatric dosage form.
• A manufacturing process that produces a measurable quality advantage.
• A technically defined excipient ratio or multilayer structure.

Routine substitution of one binder, plasticizer, filler, or enteric polymer is unlikely to support a strong composition-of-matter patent without unexpected performance data.

When did lansoprazole lose exclusivity?

Lansoprazole lost its original U.S. small-molecule exclusivity years ago. Prevacid was approved by the FDA in 1995, and generic delayed-release products entered the market after the relevant branded patents and regulatory protections expired or were successfully challenged [3,4].

The commercial market is now a mature ANDA market. Generic manufacturers compete primarily on:

• Approved strength and dosage form.
• Manufacturing cost.
• Supply reliability.
• Wholesale pricing.
• Retail and institutional contracts.
• Pediatric and swallowing-friendly presentations.
• Regulatory coverage across multiple countries.

Lansoprazole is a small molecule, so biosimilar regulation does not apply. Commercial risk comes from generic competition, not biosimilar substitution.

What is the FDA regulatory status of lansoprazole DR?

FDA-approved lansoprazole DR products include delayed-release capsules and orally disintegrating tablets. Certain products are also supplied as delayed-release oral suspension presentations or packets, depending on the approved product and market.

The principal U.S. regulatory pathway for a new generic is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence, bioequivalence, quality, and compliance with current manufacturing requirements [5].

For a lansoprazole DR product, regulatory performance depends heavily on:

• Acid-stage dissolution.
• Buffer-stage dissolution.
• Comparative impurity profile.
• Assay and content uniformity.
• Degradation under accelerated conditions.
• Residual solvents and elemental impurities.
• Multiparticulate dose uniformity.
• Capsule or tablet disintegration.
• Stability after opening or administration in food.

A product may be therapeutically equivalent while using a different excipient system from the reference product. The formulation must remain within applicable inactive-ingredient limits and meet FDA safety and quality expectations.

What FDA data are most important for an excipient-led product?

The critical package typically includes:

Data area	Commercial relevance
Comparative dissolution	Establishes release behavior against the reference product
Stability	Determines shelf life and packaging requirements
Impurity profile	Identifies lansoprazole degradation and coating-related risks
Bioequivalence	Supports ANDA approval
Inactive ingredient precedent	Reduces regulatory friction
Manufacturing validation	Demonstrates reproducible coating and dose uniformity
Container-closure compatibility	Controls moisture and oxygen exposure
Pediatric administration data	Supports labeling and commercial differentiation

A novel excipient can create a regulatory burden that exceeds its commercial value unless it delivers a clear improvement in stability, manufacturability, taste, or administration.

What commercial opportunities exist for lansoprazole DR?

Pediatric and swallowing-friendly products

Pediatric administration is one of the clearest formulation opportunities. Multiparticulate products can be administered by sprinkling pellets on approved soft foods or by dispersing the dose according to product-specific instructions. The main technical risks are premature pellet rupture, dose loss, poor palatability, and inconsistent administration.

Opportunities include:

• Smaller-dose presentations.
• Unit-dose packets.
• Better-tasting oral suspension systems.
• Reduced sedimentation.
• Simplified preparation instructions.
• Improved compatibility with feeding tubes.
• Lower-volume administration.

The product must preserve enteric integrity during preparation and administration. A liquid that destroys the coating before ingestion is not a viable DR product.

Improved stability and packaging

Lansoprazole DR products may be sensitive to moisture, heat, and alkaline or acidic microenvironments. Commercial advantages can come from:

• High-barrier blister packaging.
• Desiccant-based bottles.
• Unit-dose packaging.
• Improved seal coats.
• Lower residual moisture.
• Better pellet protection during shipping.
• Longer in-use stability after opening.

Packaging improvements can produce a more defensible market position than a minor excipient substitution because they address supply-chain performance and patient handling.

Manufacturing-cost reduction

The largest cost opportunities are process-based:

• Higher solids coating suspensions.
• Shorter coating cycles.
• Lower polymer weight gain.
• Reduced pellet attrition.
• Continuous or semi-continuous fluid-bed processing.
• Improved yield from drug layering.
• Lower-cost inert cores.
• Fewer coating stages.
• Reduced solvent-management requirements.

A lower-cost process is commercially valuable in a price-competitive generic market, provided it does not increase dissolution variability or stability failures.

Global product localization

Excipient selection must account for geographic requirements. Titanium dioxide restrictions, gelatin preferences, animal-origin controls, halal or kosher requirements, and local preservative standards can affect the target formulation.

A global platform may use:

• Hypromellose capsules instead of gelatin.
• Titanium-dioxide-free capsule shells.
• Plant-derived or synthetic alternatives.
• Region-specific coating systems.
• Separate pediatric and adult presentations.
• Packaging adapted to climate-zone stability requirements.

A single formulation may not be optimal for the United States, European Union, Japan, emerging markets, and tropical distribution channels.

Which companies are challenging or competing with lansoprazole DR?

The competitive landscape includes branded legacy products, authorized generics, large generic manufacturers, regional suppliers, and contract development and manufacturing organizations. The primary competitors are other proton-pump inhibitors, including omeprazole, esomeprazole, pantoprazole, and rabeprazole.

Product category	Competitive position
Lansoprazole DR capsules	Mature generic volume market
Lansoprazole ODT	Differentiated swallowing-friendly product
Lansoprazole oral suspension	Pediatric and institutional opportunity
Omeprazole DR	Broad generic competition and strong physician familiarity
Esomeprazole DR	Premium positioning in selected markets
Pantoprazole DR	Strong institutional and prescription presence
Rabeprazole DR	Smaller but technically comparable PPI segment

The commercial challenge is that excipient differentiation alone may not overcome low generic pricing. Products need a defined channel advantage, such as pediatric supply, hospital procurement, private-label packaging, or superior climate stability.

What generic entry risks exist for lansoprazole DR?

Generic entry risk is high because the market has mature manufacturing knowledge and multiple alternative suppliers. The principal risks are commercial and operational rather than foundational patent barriers.

Key risks include:

• Price erosion from multiple ANDA holders.
• Reference-product shortages or allocation constraints.
• Coating-process scale-up failures.
• Dissolution drift during commercial production.
• Moisture-related stability failures.
• Pediatric administration complaints.
• API supply concentration.
• Country-specific excipient restrictions.
• Inability to maintain a differentiated net price.

Paragraph IV litigation risk is generally lower for the old foundational lansoprazole products than for recently launched drugs. A Paragraph IV filing could still target a later-listed formulation or method patent, but the value of such litigation depends on the scope and remaining term of the challenged patent. The Orange Book should be checked for the specific reference product and dosage form before any launch or licensing decision [3].

How strong is the lansoprazole DR patent estate?

The molecule-level estate is weak because the original patents are expired. A new entrant should not rely on broad lansoprazole or generic enteric-coating claims.

A stronger IP strategy would focus on:

• Defined multilayer pellet architecture.
• Narrow coating-weight ranges tied to dissolution performance.
• Stabilizing excipient combinations.
• Pediatric liquid or sprinkle systems.
• Tube-administration compatibility.
• Low-moisture manufacturing.
• Continuous coating processes.
• Packaging and in-use stability.
• Narrowly claimed impurity-control methods.

The most defensible assets may be trade secrets rather than patents. Fluid-bed parameters, spray conditions, drying endpoints, and coating suspension controls can be difficult to reverse engineer even when the final excipient list is public.

What licensing deals are relevant to lansoprazole DR?

The principal licensing opportunity is no longer the active ingredient. It is the platform or product package. Potential deal structures include:

• Licensing a validated multiparticulate coating process.
• Supplying a proprietary pediatric suspension platform.
• Providing a private-label ODT formulation.
• Granting regional rights for a stable tropical-climate product.
• Licensing a non-gelatin capsule or titanium-dioxide-free presentation.
• Contract manufacturing with technology transfer.
• Co-developing a hospital or institutional unit-dose product.

Royalty economics are likely to be stronger for a differentiated dosage form than for a standard lansoprazole DR capsule. A license based only on routine enteric coating is vulnerable to rapid substitution by internal development or competing CDMOs.

Key Takeaways

• Lansoprazole DR depends on enteric-coated multiparticulates because lansoprazole is acid-labile.
• The most important excipient decisions concern alkalinity, binder selection, seal coating, enteric polymer, plasticizer, and moisture control.
• Foundational lansoprazole patents and original Prevacid exclusivity are expired.
• The product is a small molecule, so biosimilar risk does not apply.
• Generic competition is intense, making cost, supply reliability, and dosage-form differentiation central to commercial success.
• Pediatric suspension, sprinkle, ODT, feeding-tube, and climate-stable products offer the clearest opportunities.
• New patent value is more likely in a narrowly defined formulation or process than in a broad excipient substitution.
• Manufacturing parameters and coating controls may provide stronger practical protection as trade secrets.
• FDA development should prioritize comparative dissolution, stability, impurity control, and administration performance.
• Licensing value is highest for validated delivery platforms and differentiated regional products.

FAQs About Lansoprazole DR Excipients and Commercial Strategy

Can lansoprazole DR be formulated as a conventional immediate-release tablet?

Not for standard oral use without an acid-protection strategy. Immediate gastric exposure can degrade lansoprazole and compromise dose delivery. A delayed-release coating or equivalent protective system is generally required.

Is lansoprazole DR suitable for a powder-for-reconstitution product?

Yes, but the reconstituted product must maintain pellet integrity, dose uniformity, chemical stability, and appropriate administration instructions. The vehicle must not dissolve or damage the enteric coating before intestinal delivery.

Which excipient creates the greatest formulation risk?

The enteric coating system creates the greatest overall risk because polymer type, coating weight, plasticizer, seal coat, moisture, and process conditions jointly determine acid resistance and intestinal release.

Can a lansoprazole DR product avoid gelatin capsules?

Yes. Hypromellose capsules, blister-based multiparticulate systems, orally disintegrating tablets, and unit-dose suspension formats can provide non-gelatin alternatives, subject to product-specific regulatory and performance requirements.

Is an excipient patent alone enough to defend a lansoprazole DR product?

Usually not. A defensible product position generally requires a technically meaningful combination of composition, process, performance, and commercial execution. A routine excipient replacement is unlikely to create durable market exclusivity.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (1995). Prevacid approval history and prescribing information. Drugs@FDA.

5. U.S. Food and Drug Administration. (2015). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs